Tags: Cancer | smallpox | vaccine | liver | cancer

Modified Smallpox Vaccine Offers Hope Against Liver Cancer

Monday, 11 Feb 2013 07:11 AM


A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year, a study found.
The therapy from closely held Jennerex Inc., called JX-594, or Pexa-Vec, is being tested in people with advanced hepatocellular carcinoma. The 16 patients who received a high dose of the medicine lived a median 14.1 months after injection, compared with 6.7 months for 14 patients on a low dose, according to the study published Sunday by the journal Nature Medicine.
“The treatment options for advanced HCC are limited, with few promising agents currently in development,” Tony Reid, a professor at the University of California, San Diego, and co-lead author of the paper, said in a statement. The study“highlights the unique possibility of a meaningful survival benefit combined with short-term, transient, and manageable side effects.”
Hepatocellular carcinoma is a cancer that forms in the tissues of the liver and can spread to other parts of the body. The disease was diagnosed in 28,720 people in the U.S. last year, and 20,550 people died from the illness, according to the National Cancer Institute.
In the study published Sunday, patients received the medicine three times during a four-week period. About 35 percent of those in the high-dose group were alive 18 months later, the study said. The current five-year survival rate for liver patients is about 15 percent, according to the American Cancer Society.
Competing Efforts
San Francisco-based Jennerex is competing with companies including Amgen Inc., Oncolytics Biotech Inc., PsiOxus Therapeutics Ltd., and Transgene SA to develop vaccines using oncolytic tumor viruses, pathogens that infect and destroy cancer cells. The approach may enhance the tumor-fighting effects of standard treatments such as chemotherapy and radiation or work alone.
Researchers studying Jennerex’s therapy used the same strain of virus that’s used in the smallpox vaccine, called vaccinia virus, because of its natural ability to replicate in cancer cells. They modified the virus to enhance its cancer-fighting properties.
The approach differs from so-called cancer vaccines, such as Merck & Co.’s Gardasil shot that targets a virus that causes cervical cancer or Dendreon Corp.’s Provenge, which stimulates an immune response against prostate cancer cells.
While vaccinia virus is similar to smallpox, it doesn’t contain smallpox and can’t cause the disease, according to theU.S. Centers for Disease Control and Prevention.
The company’s name is based on Edward Jenner, an 18th century English scientist who developed the first vaccination with an inoculation against the related cow-pox virus.

© Copyright 2015 Bloomberg News. All rights reserved.

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
Zip Code:
Privacy: We never share your email.
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Bacteria Offer New Way to Treat Cancer: M.D. Anderson Study

Sunday, 01 Feb 2015 11:34 AM

Bacteria may offer a new way to treat cancer, a small, preliminary study suggests.

Researchers injected a wea . . .

Do You Get Winter Nose Bleeds? Here's Help

Sunday, 01 Feb 2015 11:29 AM

Nosebleeds are a common during the winter and shouldn't be cause for concern, an expert says.

Cold winter ai . . .

Drug That Fights Binge Eating OKd by FDA

Saturday, 31 Jan 2015 10:04 AM

The U.S. Food and Drug Administration on Friday approved Shire's stimulant Vyvanse to treat binge-eating disorder, the f . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

America's News Page
©  Newsmax Media, Inc.
All Rights Reserved